Core Viewpoint - SciSparc Ltd. has signed a binding term sheet to acquire a portfolio of patents, trademarks, and intellectual property rights related to innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. This acquisition aims to enhance SciSparc's capabilities in the medical device market, particularly for treating gastroesophageal reflux disease (GERD) [1][4]. Company Overview - SciSparc Ltd. operates through its majority-owned subsidiary NeuroThera Labs Inc., focusing on clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals [7]. - The company is engaged in drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder (ASD) [7]. Acquisition Details - The acquisition includes the complete portfolio of intellectual property rights associated with the MUSE™ system, which is designed for transoral fundoplication, a minimally invasive procedure for GERD treatment [2][4]. - In exchange for the acquired assets, SciSparc will issue shares representing 19.99% of its outstanding share capital to Xylo upon closing of definitive agreements [4]. Market Potential - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to grow to $3.03 billion by 2030, with a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030 [5]. - SciSparc plans to replicate Xylo's successful commercialization model from Greater China to high-growth regions such as North America, Europe, and Latin America through exclusive partnerships with regional distributors [3].

Landmark partnership brings Smart Routing™ technology to one of Canada’s fastest-growing cities with real-time connections to Brampton Transit and GO TransitTORONTO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Argo Corporation (TSXV:ARGH) (OTCQX:ARGHF) ("Argo" or the "Company"), a leader in next-generation transit solutions, today announced the launch of its Smart Routing™ pilot service in the City of Brampton. Argo connects to existing Brampton Transit routes with an on-demand, fully electric service and integrates ...

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows: Conference: Piper Sandler 37th Annual Healthcare ConferenceDate/Time: Wednesday, December 3, 2025 at 2:30 p.m. ET The ...

Core Insights - Alarum Technologies Ltd. reported significant financial growth in Q3 2025, with revenues reaching $13.0 million, an 81% increase year-over-year, and a net profit of $0.1 million [2][11] - The company is focusing on long-term market leadership in the AI training-data sector, prioritizing infrastructure investments over short-term profitability [2][6] - Strategic investments are expected to pressure gross margins and EBITDA in the near term but are aimed at positioning the company for substantial growth and margin improvement [2][6] Financial Performance - Q3 2025 revenues were $13.0 million, up from $7.2 million in Q3 2024, while total revenues for the first nine months of 2025 were $28.9 million, an 18% increase from $24.5 million in the same period of 2024 [11][10] - Gross profit for Q3 2025 was $7.2 million, compared to $5.2 million in Q3 2024, with a gross margin of 55.6% [10][16] - Adjusted EBITDA for Q3 2025 was $1.2 million, down from $1.4 million in Q3 2024, reflecting increased operating expenses due to infrastructure investments [10][16] Customer and Market Dynamics - The company experienced a 26% increase in paying customers and a 17% rise in average revenue per customer in Q3 2025 [4][8] - New AI-focused products, including DataSets and custom Scrapers, are becoming significant revenue contributors, with triple-digit growth in some areas [8][11] - Alarum's strategic decision to expand capacity and enhance infrastructure is aimed at capturing the growing demand from AI labs and enterprises [5][6] Financial Outlook - For Q4 2025, Alarum anticipates revenues of approximately $12 million, a 63% increase year-over-year, with Adjusted EBITDA expected to be around $1 million [9] - The company expects smoother and more predictable revenue growth patterns as AI models transition into production and fine-tuning cycles [9][11] Balance Sheet and Equity - As of September 30, 2025, Alarum had a robust balance sheet with $24.6 million in cash and no debt, and shareholders' equity increased to $31.1 million from $26.4 million at the end of 2024 [8][16]

Core Insights - Repligen Corporation will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Coral Gables, Florida, with CFO Jason Garland leading an analyst discussion on December 3 at 1:20 p.m. ET [1] - A live webcast of the conference will be available on Repligen's Investor Relations website, with a replay option for a limited time post-event [2] Company Overview - Repligen Corporation is a global life sciences company specializing in innovative bioprocessing technologies and systems aimed at enhancing the manufacturing efficiency of biological drugs [3] - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, focusing on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - The corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional key locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3]

Core Insights - Silexion Therapeutics Corp. is a clinical-stage biotechnology company focused on oncology, specifically targeting solid tumor cancers with the mutated KRAS oncogene [3]. Group 1: Company Presentation - Silexion management will present at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 3, 2025, from 2:30 to 2:55 PM ET [2]. - The presentation will be led by Ilan Hadar, CEO, and Mirit Horenshtein-Hadar, CFO, at Florida Atlantic University Conference Center, Boca Raton, FL [2]. - Management will be available for one-on-one meetings during the conference, and interested parties can arrange meetings through their conference representative [2]. Group 2: Clinical Development - Silexion is dedicated to developing innovative treatments for solid tumor cancers, particularly those with the mutated KRAS oncogene, which is the most common oncogenic gene driver in human cancers [3]. - The company has conducted a Phase 2a clinical trial for its first-generation product, which showed a positive trend compared to chemotherapy alone [3]. - Silexion is focused on advancing its lead product candidate for locally advanced pancreatic cancer [3].

Core Viewpoint - OBOOK Holdings Inc. (OwlTing) has authorized a share repurchase program of up to USD $10 million, reflecting the Board's belief that the current market valuation does not fully represent the company's strengths and upcoming catalysts in its payment technology pipeline [1][2]. Share Repurchase Program - The repurchase program is effective for nine months and allows the company to buy back shares through various methods, including open-market purchases and block trades, in compliance with applicable securities laws [2][4]. - The company is not obligated to repurchase a specific number of shares, and the program may be modified or terminated based on market conditions or corporate needs [5]. Strategic Roadmap - OwlTing is set to launch transformative technologies that integrate traditional financial systems, stablecoin settlements, and AI-driven payment models, positioning itself as a critical infrastructure provider for digital currency adoption [3]. - Key anticipated milestones include the integration with a major global card network for seamless digital currency settlement, the implementation of stablecoin-based settlement architecture, and the deployment of an AI-driven autonomous settlement engine [7]. Company Overview - OBOOK Holdings Inc. operates as OwlTing Group, headquartered in Taiwan, with subsidiaries in multiple countries, and is recognized as a top player in the "Enterprise & B2B" category of the stablecoin market [6]. - The company's mission is to leverage blockchain technology for reliable data management and to facilitate the digital transformation of business operations, exemplified by its hybrid payment solution, OwlPay [6].

New York, Nov. 26, 2025 (GLOBE NEWSWIRE) -- CHIJET MOTOR COMPANY, INC. (NASDAQ: CJET) (“Chijet” or the “Company”), a global automotive technology enterprise, today announced that its digital asset treasury holdings have surpassed $400 million in value. The Company has acquired 100 million tokens as part of its strategic digital asset initiative announced earlier this month, with current holdings valued at over $400 million. “Reaching $400 million in digital asset treasury value represents an important miles ...

Core Insights - Celcuity Inc. is participating in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Miami, Florida [1] - CEO Brian Sullivan will have a fireside chat on December 3, 2025, at 7:30 a.m. ET, with a live webcast available [2] Company Overview - Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications [3] - The lead therapeutic candidate, gedatolisib, is a potent pan-PI3K and mTORC1/2 inhibitor that blocks the PI3K/AKT/mTor pathway [3] - Ongoing clinical trials include VIKTORIA-1, which has completed enrollment for both PIK3CA wild-type and mutant cohorts, and VIKTORIA-2, which is currently enrolling patients [3] - A Phase 1/2 trial, CELC-G-201, is evaluating gedatolisib in combination with darolutamide for metastatic castration-resistant prostate cancer [3]

Company Overview - USA Rare Earth, Inc. is developing a rare earth sintered neo magnet manufacturing plant in Stillwater, Oklahoma, aiming to establish domestic supply, extraction, and processing capabilities for rare earth and critical minerals [3] - The company intends to supply its magnet manufacturing plant and market surplus materials to third parties, focusing on various industries including defense, automotive, aviation, industrial, AI robotics, medical, and consumer electronics [3] - USA Rare Earth's strategy aligns with national priorities, offering the potential for a sustainable and secure domestic supply of materials critical to key industries [3] Index Inclusion - USA Rare Earth has been included on the preliminary list for addition to the Russell 2000 Index, with expected effectiveness on December 22, 2025, pending FTSE Russell's standard review process [1] - Membership in the Russell 2000 Index ensures automatic inclusion in the broader Russell 3000 Index and applicable growth and value style indexes, which are widely used by investment managers and institutional investors [2]